Genmab A GMAB Institutional Ownership

Updated Oct 21, 2026

Genmab A/S (NASDAQ:GMAB) was held by 291 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Total shares held in GMAB rose 24.99% from Q1 2026; the number of holders rose 35.35% from Q2 2025.
• Looking at the 291 holders of GMAB individually, 154 added to their positions, 97 reduced their stakes and 40 left their positions unchanged.
• In total, institutional investors held 102.28Mn shares of Genmab at the end of Q2 2026, up 20.45Mn from the prior quarter and up 45.04Mn from a year earlier.
• As of June 30, 2026, Paradigm Biocapital Advisors LP held the largest stake in Genmab with 13.13Mn shares.
• Holders that added the most shares of Genmab in Q2 2026 were Paradigm Biocapital Advisors LP (+5.17Mn shares), Deerfield Management Company, L.P. (+4.4Mn shares), Sofinnova Investments, Inc. (+3.29Mn shares), Deep Track Capital, LP (+1.99Mn shares) and Two Sigma Investments, LP (+1.17Mn shares).
• The largest position reductions in GMAB for Q2 2026 were by Orbis Allan Gray Ltd (-1.56Mn shares), AllianceBernstein L.P. (-912.27K shares), Renaissance Technologies LLC (-896.7K shares), Morgan Stanley (-554.54K shares) and FMR LLC (-247.03K shares).
• Per Business Quant data, the 10 largest holders of Genmab at the end of Q2 2026 were Paradigm Biocapital Advisors LP (13.13Mn shares), Orbis Allan Gray Ltd (11.37Mn shares), AllianceBernstein L.P. (8.64Mn shares), Deerfield Management Company, L.P. (6.87Mn shares), Deep Track Capital, LP (5.65Mn shares), Arrowstreet Capital, Limited Partnership (4.98Mn shares), BlackRock, Inc. (4.67Mn shares), Sofinnova Investments, Inc. (4.05Mn shares), Renaissance Technologies LLC (3.52Mn shares) and Two Sigma Investments, LP (3.51Mn shares).